Characteristics and indications of oxcarbazepine;Características e indicaciones de la oxcarbacepina

Revista de Neurologia

Volumn 35, Issue SUPPL. 1, 2002, Pages

  Herranz, J L ^a   Argumosa, A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Carbamazepine; Epilepsy; Hyponatraemia; Oxcarbazepine; Partial seizures; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXTROPROPOXYPHENE; DIAZEPAM; ERYTHROMYCIN; ESTROGEN; ETHINYLESTRADIOL; ETHOSUXIMIDE; FELODIPINE; GABAPENTIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMOTRIGINE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VILOXAZINE; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANT THERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EPILEPSY; FOCAL EPILEPSY; HEADACHE; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; RASH; REVIEW; SEIZURE; SOMNOLENCE; VOMITING;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPILEPSY; HUMANS; ION CHANNELS; MOLECULAR STRUCTURE; PLACEBOS; TREATMENT OUTCOME;

EID: 0036764337     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40 (Suppl 5): S37-46.
2. Shorvon S. Oxcarbazepine: A review. Seizure 2000; 9: 75-9.
3. Glauser TE. Oxcarbazepine in the treatment of epilepsy. Pharmaco-Therapy 2001; 21: 904-19.
4. Faigle JW, Menge GP. Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance; comparison with carbamazepine. Int Clin Psychopharmacol 1990; 5 (Suppl 1): S73-82.
5. McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF. Oxcarbazepine: Mechanisms of action. Epilepsia 1994; 35 (Suppl 3): S5-9.
6. Wamil AW, Portet C, Jensen PK, Schmutz M, McLean MJ. Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture. Epilepsia 1991; 32 (Suppl 3): S60-5.
7. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1993; 34 (Suppl 5): S47-50.
8. Stefani A, Pisani A, DeMurtas M, Mercuri NB, Marciani MG, Calabresi P. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 1995; 36: 997-1002.
9. Schutz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica 1986; 16: 769-78.
10. Degen PH, Flesch G, Cardot JM, Czendlik C, Dieterle W. Influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharmacol Drud Dispos 1994; 15: 519-26.
11. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1995; 35 (Suppl 3): S10-3.
12. Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 1989; 37: 69-74.
13. Augusteijn R, van Parys JAP. Oxcarbazepine (Trileptal, OXC)-dos-concentration relationship in patients with epilepsy. Acta Neurol Scand 1990; 82 (Suppl 133): S34-7.
14. Larkin JG, McKee PJ, Forrest G, Beastall GH, Park BK, Lowrie JI, et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31: 65-71.
15. Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, et al. The effects of renal impairment on the pharmacokinetics of oxcarbazepine ant its metabolites. Eur J Clin Pharmacol 1994; 47: 161-7.
16. González-Esquivel DF, Ortega-Gavilán M, Alcántara-López G, Jung-Cook H. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res 2000; 31: 202-5.
17. Baruzzi A, Albani F, Riva R. Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35 (Suppl 3): S14-9.
18. Battino D, Croci D, Granata T, Bernardi G, Monza G. Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine. Ther Drug Monit 1992; 14: 376-9.
19. Sonnen AE. Oxcarbazepine and oral contraceptives. Acta Neurol Scand 1990; 82 (Suppl 133): S34-7.
20. Houtkooper MA, Lammertsma A, Meyer JWA, Goedhart DM, Meinardi H, van Oorschot CAEH, et al. Oxcarbazepine (GP 47680): A possible alternative to carbamazepine? Epilepsia 1987; 28: 693-8.
21. Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, et al. Oxcarbazepine placebo-controlled, dose-ranging trialin refractory partial epilepsy. Epilepsia 2000; 41: 1597-607.
22. Glauser TA, Nidro M, Sachdeo T, Pasteris LA, Weinstein S, AbouKhalil B, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54: 2237-44.
23. Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: A double-bold study. Epilepsy Res 1987; 1: 284-9.
24. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K (The Scandinavian Oxcarbazepine Study Group). A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6.
25. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, et al. A double-blind controlled trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-60.
26. Bill PA, Vigonius U, Pohlmann H, Guerreiro CA, Kochen S, Saffer D, et al. A double-blind controlled trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.
27. Guerreiro MM, Vigonius U, Pohlmann H, De Manreza ML, Fejerman N, Antoniuk SA, et al. A double-blind controlled trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205-13.
28. Sachdeo RG, Edwards K, Hasegawa H. Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent-onset partial epilepsy (abstract). Neurology 1999; 52 (Suppl 2): A391.
29. Schachter SC, Vazquez B, Fisher RS, Laxer KD, Montouris GD, Combs-Cantrell DT, et al. Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52: 732-7.
30. Beydoun A, Sachdeo RC, Rosenfeld WE, Krauss GL, Sessler N, Mesenbrink P, et al. Oxcarbazepine monotherapy for partial onset seizures: A multicenter, double-blind, clinical trial. Neurology 2000; 54: 2245 -51.
31. Sachdeo RC, Beydoun A, Schachter SC, Vázquez B, Schaul N, Mesenbrink P, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001; 57: 864-71.
32. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7.
33. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997; 12: 496-8.
34. Van Parys JAP, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal®) on a named-patients basis. Epilepsy Res 1994; 19: 79-85.
35. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intel Disab Res 1998; 42 (Suppl 1): S41-5.
36. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993; 34: 163-5.
37. Borusiak P, Korn-Merker E, Holert N, Boenigk HE. Hyponatremia induced by oxcarbazepine in children. Epilepsy Res 1998; 30: 241-6.
38. Isojärvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995; 47: 461-4.